Company Description
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide.
The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia.
It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others.
The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Ralph Schiess Ph.D. |
Contact Details
Address: 201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202 United States | |
| Phone | 513-620-4101 |
| Website | onconetix.gcs-web.com |
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001782107 |
| CUSIP Number | 682160106 |
| ISIN Number | US09610B1089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ralph Schiess Ph.D. | Interim Chief Executive Officer and Chief Science Officer |
| Bruce Harmon | Chief Financial Officer |
| Dr. Brian Price Ph.D. | Head of Technology Strategy |
| Frank A. Jaeger M.A., M.B.A. | Senior Vice President of Marketing and Business Development |
| Andrew D. Skibo Ph.D. | Global Head of Biologics Operations |
| Theodore Scott Yoho | Head of Business Development |
| Dr. Ali I. Fattom Ph.D. | Head of Science and Discovery |
| Dr. Jay Newmark M.B.A., M.D. | Chief Medical Officer |
| Christian Bruhlmann | Chief Strategy Officer and GM of Europe |
| Dr. Donald L. Very Jr., Ph.D. | Senior Vice President of Commercial Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 10-K | Annual Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 13, 2024 | 8-K/A | [Amend] Current report |
| Feb 27, 2024 | 8-K/A | [Amend] Current report |
| Feb 14, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 14, 2024 | PRE 14A | Other preliminary proxy statements |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 12, 2024 | 8-K | Current Report |
| Feb 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |